Effects of Pioglitazone on Inflammation in Diabetes Patients
Author Information
Author(s): Andreas Pfützner, Alexander Weise, Elisabeth Pfützner-Riehn, Georg Lübben, Michael Morcos, Efstrathios Karagiannis, Matthias Weber, Thomas Forst
Primary Institution: IKFE Institute for Clinical Research and Development
Hypothesis
Does short-term treatment with pioglitazone reduce inflammatory activation of mononuclear cells in patients with type 2 diabetes and coronary artery disease?
Conclusion
Pioglitazone rapidly reduced the inflammatory state of monocytes/macrophages and decreased cardiovascular risk markers, independent of glycemic control.
Supporting Evidence
- Patients treated with pioglitazone showed significant decreases in inflammatory markers like MMP-9 and hsCRP.
- The study demonstrated that pioglitazone improved insulin resistance and metabolic syndrome indicators.
- No significant changes in HbA1c were observed, indicating the effects were independent of blood sugar control.
- The treatment was well tolerated with no severe adverse events reported.
Takeaway
This study found that a medicine called pioglitazone can help lower inflammation in the blood for people with diabetes, even if their blood sugar levels stay the same.
Methodology
A double-blind, placebo-controlled, randomized study where patients received either pioglitazone or placebo for four weeks.
Potential Biases
Potential bias due to funding from Takeda Pharma.
Limitations
The study duration was short, and it did not observe significant changes in HbA1c levels.
Participant Demographics
63 patients (52 males, 11 females), mean age 66 years, with well-controlled type 2 diabetes and coronary artery disease.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website